Physician profile
Lindsay Tom
NPI 1053826008
$71,088.46
in general payments reported to CMS, 2019-2025
40 companies · $36K in 2025
The $36K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,166 · 2022: $7,347 · 2023: $6,611 · 2024: $16K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $16K · Consulting Fee: $11K · Travel and Lodging: $6,340 · Education: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,358.00 |
| Food and Beverage | $16,322.33 |
| Consulting Fee | $11,286.00 |
| Travel and Lodging | $6,339.82 |
| Education | $269.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $34,172.80 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $8,775.59 | 2021-2025 | |
| Ucb, INC. | $7,428.28 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $5,941.83 | 2021-2025 | |
| Amgen INC. | $3,726.61 | 2021-2025 | Enbrel, Tavneos, Otezla |
| Mallinckrodt Hospital Products INC. | $2,111.00 | 2021-2025 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $1,166.29 | 2021-2025 | Orencia, Sotyktu |
| Lilly USA, LLC | $1,070.44 | 2021-2024 | Taltz, Zepbound |
| Astrazeneca Pharmaceuticals LP | $853.09 | 2021-2025 | Saphnelo |
| Radius Health, INC. | $831.22 | 2021-2025 | Tymlos |
| Horizon Therapeutics Plc | $726.74 | 2021-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $726.73 | 2021-2025 | Benlysta, Nucala |
| Aurinia Pharma U.S., INC. | $600.75 | 2021-2024 | Lupkynis |
| Ani Pharmaceuticals, INC. | $481.71 | 2022-2025 | Purified Cortrophin Gel |
| Pfizer INC. | $393.53 | 2021-2024 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $315.67 | 2021-2024 | |
| Janssen Scientific Affairs, LLC | $276.14 | 2022-2025 | Tremfya |
| Sandoz INC. | $259.55 | 2022-2025 | Hyrimoz, Jubbonti |
| Idorsia Pharmaceuticals US INC | $190.13 | 2022-2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.89 | 2022-2025 | Ofev, Jascayd |
| Organon LLC | $100.44 | 2022-2025 | Renflexis |
| Fresenius Kabi USA, LLC | $91.24 | 2024-2025 | Idacio |
| Janssen Pharmaceuticals, INC | $71.44 | 2025 | Tremfya |
| Depuy Synthes Sales INC. | $68.88 | 2024 | Orthovisc, Monovisc, Peak |
| Kyowa Kirin, INC. | $66.32 | 2023-2024 | Crysvita |
| Genentech USA, INC. | $63.91 | 2023-2025 | Actemra |
| Hikma Pharmaceuticals USA | $59.32 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.35 | 2025 | Hyqvia |
| Eisai INC. | $51.88 | 2021 | |
| Alexion Pharmaceuticals, INC. | $48.13 | 2022-2023 | Strensiq |
| Ultragenyx Pharmaceutical INC. | $46.82 | 2022 | |
| Csl Behring | $38.96 | 2021-2023 | Haegarda |
| Cumberland Pharmaceuticals, INC. | $24.91 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $22.00 | 2025 | Simlandi |
| Pacira Therapeutics, INC. | $21.80 | 2021 | |
| Biocon Biologics INC | $20.83 | 2023 | Hulio |
| Invivyd INC | $19.00 | 2025 | Pemgarda |
| Azurity Pharmaceuticals, INC. | $14.30 | 2023 | Horizant |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.08 | 2021 | |
| Octapharma USA, INC. | $12.86 | 2023 | Octagam Immune Globulin (Human) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Tom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.